Wanbury Ltd , a prominent pharmaceutical company, has taken a significant step towards digital transformation by successfully implementing SAP S/4HANA Private Cloud system. This strategic move, announced on October 3, 2025, marks a major milestone in the company's efforts to enhance its operational efficiency and future-readiness.

Key Highlights of the Implementation

• System Go-Live: Wanbury Ltd successfully went live with its new Enterprise Resource Planning (ERP) system on October 3, 2025.
• Strategic Partner: Deloitte supported the implementation, serving as the strategic partner to enable Wanbury's vision of an agile, intelligent, and future-ready enterprise platform.
• Transition Plan: The migration from the previous SAP ECC system to SAP S/4HANA followed a structured transition plan, including mandatory blackout days on October 1st and 2nd.

Expected Benefits

The new SAP S/4HANA Private Cloud system is anticipated to bring several advantages to Wanbury Ltd:

1. Enhanced operational efficiency
2. Improved transparency across functions
3. Better data visibility for decision-making
4. Strengthened process integration
5. Scalable platform to support future growth initiatives
6. Increased compliance in the pharmaceutical landscape
7. Greater agility in adapting to market dynamics

Management's Perspective

Mr. Mohan Rayana, Director of Wanbury Ltd, commented on this significant development:

"The implementation of SAP S/4HANA Private Cloud marks a significant milestone in Wanbury's digital transformation journey. This strategic investment will strengthen our operational backbone, enhance transparency, and enable us to serve our customers, partners, and stakeholders with greater efficiency. With this future-ready platform, we are well-positioned to adapt to market dynamics, strengthen stakeholder trust, and accelerate sustainable growth."

About Wanbury Ltd

Wanbury Ltd, established in 1988, is a leading pharmaceutical company. The company has a strong presence in both the global API market and domestic branded formulations.

This strategic implementation of SAP S/4HANA Private Cloud system underscores Wanbury Ltd's commitment to leveraging technology for operational excellence and sustainable growth in the competitive pharmaceutical industry.

Wanbury Limited , a prominent player in the pharmaceutical sector, has reported a remarkable financial performance for the first quarter. The company's consolidated net profit surged to ₹135.00 crore, marking a significant increase from ₹10.40 crore in the same period last year.

Revenue Growth

The company's revenue showed robust growth, reaching ₹1.60 billion compared to ₹1.30 billion in the corresponding quarter of the previous year. This represents a year-over-year increase of approximately 23%.

Improved Profitability

Wanbury's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) more than doubled, rising to ₹244.00 crore from ₹110.00 crore in the same quarter last year. This substantial increase in EBITDA reflects the company's improved operational efficiency and cost management.

Margin Expansion

The EBITDA margin saw a significant expansion, reaching 14.98% compared to 8.37% in the previous year. This margin improvement of over 660 basis points indicates the company's ability to enhance its profitability while growing its revenue.

Financial Position

According to the unaudited standalone financial results:

The standalone results show a substantial improvement in profitability, with profit after tax increasing by over 1200% year-over-year.

Conclusion

Wanbury Limited's first-quarter performance demonstrates strong growth across key financial metrics. The substantial increase in net profit, coupled with robust revenue growth and margin expansion, positions the company favorably. Investors and stakeholders will likely be watching closely to see if this momentum can be sustained in the coming quarters.

Note: All figures are based on the consolidated results unless otherwise specified.